An Overview of the Curcumin-Based and Allicin Bioactive Compounds as potential treatment to SARS-CoV-2 with structural bioinformatics tools
The recent outbreak of SARS-CoV-2 across the globe and the absence of a specific cure against the disease lead the scientific community to investigate some alternative indigenous treatments. SARS-CoV-2 is the virus responsible for the coronavirus ailment 2019 (COVID-19). This virus has 4 auxiliary proteins namely the S (spike), E (envelope), M (membrane), and N (nucleocapsid) proteins. The main proteases and RNA dependent RNA polymerase are also essential structures by which the virus replicates and survives. Each of these proteins are structures of the virus that are potential targets for drugs which are leads in the drug discovery process of any drug for the virus. Currently available treatments are not specific to the disease and therefore carry unwanted adverse effects that can be highly dangerous and sometimes fatal. Many of these treatments are supplementary in nature or based on repurposed drugs from other viral outbreaks. Alternatives of conventional drugs are required to control the spread and severity of the disease. Allicin, curcumin and their derivatives have been researched for their antiviral property and shown to have good binding affinity towards SARS-CoV-2 structures essential in their survival, especially the main proteases and RNA dependent RNA polymerases. The structural bioinformatics tools have elicited methods to predict the bioactivity of the natural product-based compounds. Apart from the beneficial medication that they offer, natural products carry along other advantages for the current pandemic situation in terms of supply, logistics, and affordability.
There is no Figure or data content available for this article
2. Fauci AS. The story behind COVID-19 vaccines. Science (80- ). 2021;372(6538):109-109. doi:10.1126/science.abi8397
3. Ansori ANM, Kharisma VD, Antonius Y, Tacharina MR, Rantam FA. Immunobioinformatics analysis and phylogenetic tree construction of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Indonesia: spike glycoprotein gene. J Teknol Lab. 2020;9(1):13-20. doi:10.29238/teknolabjournal.v9i1.221
4. Parikesit AA. Introductory Chapter: The Contribution of Bioinformatics as Blueprint Lead for Drug Design. In: Ivana Glavic, ed. Molecular Insight of Drug Design. InTech; 2018:7. doi:10.5772/intechopen.79664
5. Nguyen HL, Thai NQ, Truong DT, Li MS. Remdesivir strongly binds to both RNA-Dependent RNA Polymerase and main protease of SARS-CoV-2: evidence from molecular simulations. J Phys Chem B. 2020;124(50):11337-11348. doi:10.1021/acs.jpcb.0c07312
6. Parikesit AA, Nurdiansyah R. Drug repurposing option for COVID-19 with structural bioinformatics of chemical interactions approach. Cermin Dunia Kedokt. 2020;47(3):222-226. doi:10.5281/zenodo.4460736
7. Amin SA, Jha T. Fight against novel coronavirus: A perspective of medicinal chemists. Eur J Med Chem. 2020;201:112559. doi:10.1016/j.ejmech.2020.112559
8. Arakawa T, Yamasaki H, Ikeda K, Ejima D, Naito T, Koyama AH. Antiviral and virucidal activities of natural products. Curr Med Chem. 2009;16(20):2485-2497. doi:10.2174/092986709788682065
9. Parikesit AA, Nurdiansyah R, Agustriawan D. Telaah sistematis terhadap basis data bahan alam untuk pengembangan produk suplemen herbal. Pros SEMNASTAN. 2018;0(0):62-68.
10. Amit Koparde A, Chandrashekar Doijad R, Shripal Magdum C. Natural Products in Drug Discovery. In: Pharmacognosy - Medicinal Plants. IntechOpen; 2019. doi:10.5772/intechopen.82860
11. Mustarichie R, Levitas J, Arpina J, Mustarichiei R, Levitas J, Arpina J. In silico study of curcumol, curcumenol, isocurcumenol, and Î²-sitosterol as potential inhibitors of estrogen receptor alpha of breast cancer. Med J Indones. 2014;23(1):15. doi:10.13181/mji.v23i1.684
12. Ullrich S, Nitsche C. The SARS-CoV-2 main protease as drug target. Bioorg Med Chem Lett. 2020;30(17):127377. doi:10.1016/J.BMCL.2020.127377
13. Ahmad J, Ikram S, Ahmad F, Rehman IU, Mushtaq M. SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) â€“ A drug repurposing study. Heliyon. 2020;6(7):e04502. doi:10.1016/J.HELIYON.2020.E04502
14. Ahmed MH, Hassan A. Dexamethasone for the treatment of coronavirus disease (COVID-19): A review. SN Compr Clin Med. 2020;2(12):2637-2646. doi:10.1007/s42399-020-00610-8
15. Omokhua-Uyi AG, Staden J Van. Natural product remedies for COVID-19: A focus on safety. South African J Bot. 2021;139:386. doi:10.1016/J.SAJB.2021.03.012
16. Lung J, Lin Y, Yang Y, et al. The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase. J Med Virol. Published online March 2020:jmv.25761. doi:10.1002/jmv.25761
17. Bastikar VA, Bastikar A V., Chhajed SS. Understanding the role of natural medicinal compounds such as curcumin and allicin against SARS-CoV-2 proteins as potential treatment against COVID-19: An in silico approach. J Proteomics Bioinform. 2020;0(0):1-14. doi:10.35248/0974-276X.1000510
18. Khubber S, Hashemifesharaki R, Mohammadi M, Gharibzahedi SMT. Garlic (Allium sativum L.): A potential unique therapeutic food rich in organosulfur and flavonoid compounds to fight with COVID-19. Nutr J 2020 191. 2020;19(1):1-3. doi:10.1186/S12937-020-00643-8
19. Patel A, Rajendran M, Shah A, Patel H, Pakala SB, Karyala P. Virtual screening of curcumin and its analogs against the spike surface glycoprotein of SARS-CoV-2 and SARS-CoV. J Biomol Struct Dyn. Published online 2020:1. doi:10.1080/07391102.2020.1868338
20. Zomer R. A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19 - Tabular View - ClinicalTrials.gov. Published 2021. Accessed September 23, 2021. https://clinicaltrials.gov/ct2/show/record/NCT04382040
21. Eastman RT, Roth JS, Brimacombe KR, et al. Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci. 2020;6(5):672-683. doi:10.1021/ACSCENTSCI.0C00489
22. Meeran MFN, Javed H, Sharma C, et al. Can Echinacea be a potential candidate to target immunity, inflammation, and infection - The trinity of coronavirus disease 2019. Heliyon. 2021;7(2). doi:10.1016/J.HELIYON.2021.E05990
23. Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 Novel coronavirus in the United States. https://doi.org/101056/NEJMoa2001191. 2020;382(10):929-936. doi:10.1056/NEJMOA2001191
24. Parikesit AA. Introductory Chapter: The Emerging Corner of the Omics Studies for Rational Drug Design. In: Parikesit AA, ed. Drug Design: Novel Advances in the Omics Field and Applications. IntechOpen; 2021:4. doi:10.5772/INTECHOPEN.95544
25. Yanuar A, Munâ€™im A, Lagho ABA, Syahdi RR, Rahmat M, Suhartanto H. Medicinal plants database and three dimensional structure of the chemical compounds from medicinal plants in Indonesia. Int J Comput Sci. 2011;8(5):180-183.
26. Syahdi RR, Iqbal JT, Munim A, Yanuar A. HerbalDB 2.0: Optimization of construction of three-dimensional chemical compound structures to update Indonesian medicinal plant database. Pharmacogn J. 2019;11(6):1189-1194. doi:10.5530/pj.2019.11.184
27. Parikesit AA. Protein domain annotations of the SARS-CoV-2 proteomics as a blue-print for mapping the features for drug and vaccine designs. J Mat dan Sains. 2020;25(2):26-32. doi:10.17632/95nwwzdcsc.1
28. Parikesit AA, Agustriawan D, Nurdiansyah R. Protein annotation of breast-cancer-related proteins with machine-learning tools. Makara J Sci. 2020;24(2):6. doi:10.7454/mss.v24i1.12106
29. Stephanie F, Saragih M, Tambunan USF. Recent progress and challenges for drug-resistant tuberculosis treatment. Pharmaceutics. 2021;13(5):592. doi:10.3390/pharmaceutics13050592
30. Saragih M, Stephanie F, Alkaff AH, Tambunan USF. Identification of novel peptides targeting DNA methyltransferase 1 (DNMT-1) for breast cancer treatment. Rev Bras Farmacogn. 2020;30(5):641-651. doi:10.1007/s43450-020-00086-6
31. Saudale FZ, Lerrick RI, Parikesit AA, Mariti F. Chemistry teachersâ€™ awareness, understanding, and confidence toward computational tools for molecular visualization. J Pendidik IPA Indones. 2019;8(4):436-446. doi:10.15294/jpii.v8i4.21437
32. Adisurja GP, Parkesit AA. Virtual screening of the flavonoids compounds with the SARS-CoV-2 3C-like protease as the lead compounds for the COVID-19. Coronaviruses. 2021;02. doi:10.2174/2666796702666210222105547
33. Parikesit AA, Nurdiansyah R. Natural products repurposing of the H5N1-based lead compounds for the most fit inhibitors against 3C-like protease of SARS-CoV-2. J Pharm Pharmacogn Res. 2021;9(5):730-745.
34. Pettersen EF, Goddard TD, Huang CC, et al. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 2021;30(1):70-82. doi:10.1002/PRO.3943
35. BJ O, AO A, IF O. Pharmacoinformatics and hypothetical studies on allicin, curcumin, and gingerol as potential candidates against COVID-19-associated proteases. J Biomol Struct Dyn. 2020. doi:10.1080/07391102.2020.1813630
36. Kehinde I, Ramharack P, Nlooto M, Gordon M. The pharmacokinetic properties of HIV-1 protease inhibitors: A computational perspective on herbal phytochemicals. Heliyon. 2019;5(10). doi:10.1016/J.HELIYON.2019.E02565
37. Rosmalena R, Elya B, Dewi BE, et al. The antiviral effect of indonesian medicinal plant extracts against dengue virus in vitro and in silico. Pathogens. 2019;8(2). doi:10.3390/pathogens8020085
38. Younas M, Hano C, Giglioli-Guivarcâ€™h N, Abbasi BH. Mechanistic evaluation of phytochemicals in breast cancer remedy: current understanding and future perspectives. RSC Adv. 2018;8(52):29714-29744. doi:10.1039/C8RA04879G
How to Cite This
Copyright and Permissions
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.
JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.
JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:
- BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- SA: If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.